161 related articles for article (PubMed ID: 15717632)
1. The effect of high-flux hemodialysis on dialysis-associated amyloidosis.
Ayli M; Ayli D; Azak A; Yüksel C; Atilgan G; Dede F; Akalin T; Abayli E; Camlibel M
Ren Fail; 2005; 27(1):31-4. PubMed ID: 15717632
[TBL] [Abstract][Full Text] [Related]
2. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
3. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
4. Effects of low- and high-flux dialyzers on oxidative stress and insulin resistance.
Chu PL; Chiu YL; Lin JW; Chen SI; Wu KD
Blood Purif; 2008; 26(2):213-20. PubMed ID: 18285698
[TBL] [Abstract][Full Text] [Related]
5. The effect of on-line high-flux hemofiltration versus low-flux hemodialysis on mortality in chronic kidney failure: a small randomized controlled trial.
Santoro A; Mancini E; Bolzani R; Boggi R; Cagnoli L; Francioso A; Fusaroli M; Piazza V; Rapanà R; Strippoli GF
Am J Kidney Dis; 2008 Sep; 52(3):507-18. PubMed ID: 18617304
[TBL] [Abstract][Full Text] [Related]
6. Beta2-microglobulin amyloidosis in hemodialysis and peritoneal dialysis patients.
Dervisoglu E; Anik Y; Erdogan S; Akansel G; Yilmaz A
Ther Apher Dial; 2008 Aug; 12(4):306-10. PubMed ID: 18789118
[TBL] [Abstract][Full Text] [Related]
7. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease.
Liakopoulos V; Eleftheriadis T; Kyropoulos T; Voliotis G; Potamianos S; Zengos N; Stefanidis I; Heintz B
Ren Fail; 2005; 27(3):315-21. PubMed ID: 15957549
[TBL] [Abstract][Full Text] [Related]
8. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever.
Sahin S; Sahin GM; Ergin H; Kantarci G
Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446
[TBL] [Abstract][Full Text] [Related]
9. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular but not high-molecular advanced glycation end products (AGEs) are removed by high-flux dialysis.
Gerdemann A; Lemke HD; Nothdurft A; Heidland A; Münch G; Bahner U; Schinzel R
Clin Nephrol; 2000 Oct; 54(4):276-83. PubMed ID: 11076103
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance.
Mudge DW; Rogers R; Hollett P; Law B; Reiger K; Petrie JJ; Price L; Johnson DW; Campbell SB; Isbel NM; Sullivan M; Hawley CM
Nephrol Dial Transplant; 2005 Oct; 20(10):2178-85. PubMed ID: 16030045
[TBL] [Abstract][Full Text] [Related]
12. Beta-2 microglobulin levels in hemodialysis patients.
Mumtaz A; Anees M; Bilal M; Ibrahim M
Saudi J Kidney Dis Transpl; 2010 Jul; 21(4):701-6. PubMed ID: 20587875
[TBL] [Abstract][Full Text] [Related]
13. The effect of hollow-fiber dialyzer Plivadial Altra-Flux 140 on beta-2-microglobulin removal.
Kes P; Zubcić A; Ratković-Gusić I; Prsa M; Sefer S
Acta Med Croatica; 1997; 51(2):105-9. PubMed ID: 9204596
[TBL] [Abstract][Full Text] [Related]
14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
15. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study.
Cheung AK; Rocco MV; Yan G; Leypoldt JK; Levin NW; Greene T; Agodoa L; Bailey J; Beck GJ; Clark W; Levey AS; Ornt DB; Schulman G; Schwab S; Teehan B; Eknoyan G
J Am Soc Nephrol; 2006 Feb; 17(2):546-55. PubMed ID: 16382021
[TBL] [Abstract][Full Text] [Related]
16. The impact of dialysis modality on skin hyperpigmentation in haemodialysis patients.
Moon SJ; Kim DK; Chang JH; Kim CH; Kim HW; Park SY; Han SH; Lee JE; Yoo TH; Han DS; Kang SW
Nephrol Dial Transplant; 2009 Sep; 24(9):2803-9. PubMed ID: 19342419
[TBL] [Abstract][Full Text] [Related]
17. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
Pellicano R; Polkinghorne KR; Kerr PG
Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
[TBL] [Abstract][Full Text] [Related]
18. Relative importance of residual renal function and convection in determining beta-2-microglobulin levels in high-flux haemodialysis and on-line haemodiafiltration.
Fry AC; Singh DK; Chandna SM; Farrington K
Blood Purif; 2007; 25(3):295-302. PubMed ID: 17622712
[TBL] [Abstract][Full Text] [Related]
19. [Factors which influence phosphorus removal in hemodialysis].
Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
[TBL] [Abstract][Full Text] [Related]
20. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis.
Krane V; Krieter DH; Olschewski M; März W; Mann JF; Ritz E; Wanner C
Am J Kidney Dis; 2007 Feb; 49(2):267-75. PubMed ID: 17261429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
